TABLE 3.
Clinical Outcomes According to Baseline Albumin (N=264)
| Outcome (95% CI) |
||||
|---|---|---|---|---|
| Group | Median OS, Months | Median TTP, Months | ORR, % | DCR, %a |
| All patients (N=264) | ||||
| b-alb ≥3.4 g/dL | 9.6 (8.5-11.1) | 5.8 (5.1-6.6) | 24 (18-30) | 65 (58-71) |
| b-alb <3.4 g/dL | 4.9 (3.4-8.0) | 3.4 (2.2-7.3) | 10 (3-21) | 43 (29-58) |
| P b | .0005 | .04 | .043 | .007 |
| Group 1 (B) (N = 167) | ||||
| b-alb ≥3.4 g/dL | 10.2 (8.6-11.9) | 6.2 (5.6-7.6) | 28 (21-37) | 71 (62-78) |
| b-alb <3.4 g/dL | 4.1 (2.8-8.4) | 3.7 (2.0-7.6) | 11 (3-27) | 46 (29-63) |
| P b | .0001 | .0488 | .051 | .007 |
| Group 2 (no B) (N=97) | ||||
| b-alb ≥3.4 g/dL | 8.9 (7.8-11.1) | 4.7 (3.6-6.4) | 18 (10-28) | 56 (45-67) |
| b-alb <3.4 g/dL | 5.1 (3.8-16.0) | 3.4 (1.8-NA) | 6 (0.2-30) | 44 (20-70) |
| P b | .43 | .17 | .28 | .36 |
Abbreviations: 95% CI, 95% confidence interval; B, bevacizumab, b-alb, baseline serum albumin; DCR, disease control rate; NA, not available; ORR, overall response rate; OS, overall survival; TTP, time to disease progression.
a
DCR indicates partial response and stable disease with a duration of ≥16 weeks.
b
Bold type indicates statistical significance.